[关键词]
[摘要]
目的 探讨鼠神经生长因子联合神经节苷脂对早产儿脑神经功能的调节作用。方法 选择2017年6月—2019年6月商洛市中心医院收治的早产儿86例,随机分为两组,每组各43例。对照组静脉滴注单唾液酸四己糖神经节苷脂钠注射液,将20 mg药物混入10%葡萄糖注射液20 mL中静脉滴注,对于病情严重的患儿可增加1~2个疗程。观察组在对照组治疗的基础上联合使用注射用鼠神经生长因子,每瓶用2 mL氯化钠注射液溶解后肌肉注射,1次/d。两组患儿连续治疗10 d为1个疗程,共治疗3个疗程。观察两组患者的临床疗效,比较两组患儿的临床症状恢复时间、神经损伤标志物水平和NBNA评分。结果 治疗后,观察组新生儿临床治疗总有效率为90.70%,明显高于对照组的69.77%(P<0.05)。治疗后,观察组新生儿意识恢复时间、吮吸能力恢复时间、原始反射恢复时间和肌张力恢复时间均明显少于对照组(P<0.05)。治疗后,两组新生儿血清髓鞘碱性蛋白(MBP)、S-100β蛋白水平均明显降低(P<0.05),观察组降低程度更为显著(P<0.05)。治疗后,两组早产儿NBNA评分逐渐升高且高于治疗前(P<0.05),观察组改善程度优于对照组(P<0.05)。结论 鼠神经生长因子联合神经节苷脂治疗早产儿后能够明显降低早产儿神经损伤标志物MBP、S-100β水平,缩短神经功能恢复时间,提高NBNA评分,提高临床治疗效果,可推广使用。
[Key word]
[Abstract]
Objective To investigate the regulation of mouse nerve growth factor combined with gangliosides on the neurological function of premature infants. Methods A total of 86 cases of premature infants admitted to Shangluo Central Hospital from June 2017 to June 2019 were randomly divided into two groups, each group had 43 cases. Patients in the control group were given intravenous infusion of Monosialotetrahexosylganglioside Sodium Injection, 20 mg added into 10% glucose injection 20 mL, which could add 1 to 2 courses of treatment for severely ill children. Patients in the observaton group were given intravenous infusion of Mouse Nerve Growth Factor for Injection on the basis of control group, and each bottle was dissolved with 2 mL sodium chloride injection and intramuscular injection, once daily. Two groups of children were treated for 10 consecutive days for one course of treatment, a total of three courses of treatment. After treatment, the clinical efficacy was evaluated, and the clinical symptom recovery time, nerve injury marker level, and NBNA score in two groups were compared. Results After treatment, the total effective rate of neonatal clinical treatment in the observation group was 90.70%, which was significantly higher than 69.77% in the control group (P<0.05). After treatment, the recovery time of neonatal consciousness, sucking ability, original reflex, and the recovery time of muscle tension in the observation group were significantly less than those in the control group (P<0.05). After treatment, the levels of MBP and S-100β protein in two groups were significantly decreased (P<0.05), and and the decrease was more significant in the observation group (P<0.05). After treatment, NBNA score of premature infants in two groups were increased gradually and it was higher than that before treatment (P<0.05), and the improvement degree in the observation group was better than that in the control group (P<0.05). Conclusion Mouse nerve growth factor combined with ganglioside can significantly reduce the levels of nerve injury markers MBP and S-100β in premature infants, shorten the recovery time of neurological function, improve the NBNA score, and improve the clinical therapeutic effect, which can be widely used.
[中图分类号]
[基金项目]
陕西省卫生健康科研基金项目(2018C006)